

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

OCT 31 2003

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

## Complete if Known

Application Number 10/620,273  
Filing Date July 15, 2003  
First Named Inventor Collins, *et al.*  
Group Art Unit Unassigned 1616  
Examiner Name Unassigned D. Jones  
Attorney Docket Number 07959.105018 COP 1000 DIV 5

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PG	AA	3,936,440		NATH	02-03-1976	
	AB	3,981,863		NISWENDER, <i>et al.</i>	09-21-1976	
	AC	4,209,614		BERNSTEIN, <i>et al.</i>	06-24-1980	
	AD	4,279,859		GUTCHO, <i>et al.</i>	07-21-1981	
	AE	4,283,342		YOLLES	08-11-1981	
	AF	4,301,140		FRANK, <i>et al.</i>	11-17-1981	
	AG	4,465,775		HOUTS	08-14-1984	
	AH	5,308,606		WILSON, <i>et al.</i>	05-03-1994	
	AI	5,405,839		TORAYA, <i>et al.</i>	04-11-1995	
	AJ	5,428,023		RUSSELL-JONES, <i>et al.</i>	06-27-1995	
	AA	5,449,720		RUSSELL-JONES, <i>et al.</i>	09-12-1995	
	AK	5,548,064		RUSSELL-JONES, <i>et al.</i>	08-20-1996	
	AL	5,574,018		HABBERFIELD, <i>et al.</i>	11-12-1996	
	AM	5,589,463		RUSSELL-JONES, <i>et al.</i>	12-31-1996	
	AN	5,739,313		COLLINS, <i>et al.</i>	04-01-1993	
	AO	5,807,832		RUSSELL-JONES, <i>et al.</i>	09-15-1998	
	AP	5,840,880		MORGAN, <i>et al.</i>	11-24-1998	
	AQ	5,869,465		MORGAN, <i>et al.</i>	02-09-1999	
	AR	5,869,466		RUSSELL-JONES, <i>et al.</i>	02-09-1999	
	AS	5,936,082		BAUER	8/10/1999	
	AT	6,004,533		COLLINS, <i>et al.</i>	12-21-1999	
	AU	6,083,926		MORGAN, <i>et al.</i>	07-04-2000	
	AV	6,096,290		COLLINS, <i>et al.</i>	08-01-2000	
	AW	6,150,341		RUSSELL-JONES, <i>et al.</i>	11-21-2000	
	AX	6,211,355		COLLINS, <i>et al.</i>	04-03-2001	
	AY	6,262,253		RUSSELL-JONES, <i>et al.</i>	07-17-2001	
	AZ	6,315,978		GRISSOM, <i>et al.</i>	11-13-01	
PG	AAA	6,613,305		COLLINS, <i>et al.</i>	09-02-2003	

Examiner Signature

D. Jones

Date Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

OCT 31 2003

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

## Complete if Known

Application Number	10/620,273
Filing Date	July 15, 2003
First Named Inventor	C Illins, et al.
Group Art Unit	Unassigned - 11616
Examiner Name	Unassigned - Jones
Attorney Docket Number	07959.105018 COP 1000 DIV 5

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office	Number	Kind Code (if known)				
DA	BA	EP	0005834		BERNSTEIN, et al.	12-12-1979		
	BB	JP	58-046027		AKIRA, et al.	09-14-1981		
	BC	EP	0069450		HOUTS	01-12-1983		
	BD	EP	0165716		OLSON, et al.	12-27-1985		
	BE	WO	89/01475		PARKER, et al.	02-23-1989		
	BF	WO	92/13571		WILSON, et al.	08-20-1992		
	BG	WO	94/27613		RUSSELL-JONES, et al.	12-08-1994		
	BH	WO	94/27641		RUSSELL-JONES, et al.	12-08-1994		
	BI	WO	95/27723		MORGAN, et al.	10-19-1995		
	BJ	WO	96/31243		EDWARDS, et al.	10-10-1996		
	BK	WO	97/14711		MORGAN, et al.	04-24-1997		
	BL	WO	97/18231		COLLINS, et al.	05-22-1997		
	BM	WO	98/08859		GRISSOM, et al.	03-05-1998		
	BN	WO	99/65930		RUSSELL-JONES, et al.	12-23-1999		
	BO	WO	01/30967		GRISSOM, et al.	05-03-2001		
	BP	WO	01/28592		COLLINS, et al.	04-26-2001		
	BQ	WO	01/28595		COLLINS, et al.	04-26-2001		
	BR	WO	01/17694		COLLINS, et al.	12-06-2001		
	BS	WO	01/92288		COLLINS, et al.	12-06-2001		
DA	BT	WO	02/42318		COLLINS, et al.	05-30-2002		
	BU	WO	02/55530		COLLINS, et al.	07-18-2002		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
DA	BV	ALVAREZ, J., et al., "On a new radiopharmaceutical for kidney imaging", <i>Int'l J. of Applied Radiation and Isotopes</i> , 25, 283-284 (1974).	

Examiner Signature

*W Jones*

Date Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

## Complete if Known

Application Number	10/620,273
Filing Date	July 15, 2003
First Named Inventor	Collins, et al.
Group Art Unit	Unassigned Jelp
Examiner Name	Unassigned Jones
Attorney Docket Number	07959.105018 COP 1000 DIV 5

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
✓	CA	AMAGASAKI, T., et al., "Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells", <i>Blood</i> , 76, 1380-1386 (October, 1990).	
✓	CB	ANDERSON, C.J., et al., "Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab') <sub>2</sub> ", <i>J. Nuc. Med.</i> , 36, 850-858 (May 1985).	
	CC	ANTON, D.L., et al., "Carbon-13 nuclear magnetic resonance studies of the monocarboxylic acids of cyanocobalamin, assignments of the b-, d-, and 3-monocarboxylic acids", <i>J. Am. Chem. Soc.</i> , 102, 2215-2219 (March, 1980)	
	CD	ANTON, D.L., et al., "The synthesis and properties of four spin-labeled analogs of adenosylcobalamin", <i>J. Biol. Chem.</i> , 255, 4507-4510 (May, 1980).	
	CE	BEGLEY, J.A., et al., "Cobalamin metabolism in cultured human chorionic villus cells", <i>J. Cell. Physiol.</i> , 156, 43-47 (1993).	
	CF	BLOMQUIST, L., et al., "Uptake of labeled vitamin B12 and 4-iodophenylalanine in some tumours of mice", <i>Experientia</i> , 25, 294, 296 (1969).	
	CG	COOPER, B.A., et al., "Selective uptake of specifically bound cobalt-58 vitamin B12 by human and mouse tumour cells", <i>Nature</i> , 191, 393-395 (July, 1961).	
	CH	COOPERMAN, J.M., "Distribution of radioactive and nonradioactive vitamin B12 in normal and malignant tissues of an infant with neuroblastoma", <i>Cancer Research</i> , 32, 167-172 (January, 1972).	
	CI	COOPERMAN, J.M., et al., "Distribution of radioactive and nonradioactive vitamin B12 in the dog", <i>J. Biol. Chem.</i> , 235, 191-194 (January, 1960).	
	CJ	FLODH, H., "Accumulation of labeled vitamin B12 in some transplanted tumours", in <i>Distribution and Kinetics of Labelled Vitamin B12</i> , <i>Acta Radiologica, Supplementum</i> 284, 55-60 (1968).	
	CK	FLODH, et al., "Accumulation of labeled vitamin B12 in some transplanted tumours", <i>Int. J. Cancer</i> , 3, 694-499 (1968).	
	CL	KAPLAN, M.A., et al., "Absorption studies of 59Fe and 58Co vitamin B12 by whole-body radiometry in the radiation therapy of collum carcinoma", <i>Radiobiol. Radiother.</i> , 24, Abstract 745 (1983).	
	CM	KIKUGAWA, K., et al., "Direct halogenation of sugar moiety of nucleosides", <i>Tetrahedron Letters</i> , 2, 87-97 (1971).	
✓	CN	KOLLMER, W.E., et al., "On a new radiopharmaceutical for kidney imaging", <i>Int. J. Applied Radiation and Isotopes</i> , 25(6), 283-285 (1974).	
✓	CO	LINDEMANS, J., et al., "Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effect of differentiation induction", <i>Experimental Cell Research</i> , 184, 449-460 (1989).	

Examiner  
Signature

*R Jones*

Date  
Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

4

## Complete if Known

Application Number	10/620,273
Filing Date	July 15, 2003
First Named Inventor	Collins, et al.
Group Art Unit	Unassigned 11614
Examiner Name	Unassigned D. Jones
Attorney Docket Number	07959.105018 COP 1000 DIV 5

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
DA	DA	PONTO, J.A., "II. Schilling Test", in <i>Pharmaceutical in Medical Imaging</i> , D.P. Swanson, et al., (eds.), MacMillan Publishing Co., Inc., New York, pp. 621-628 (1990).	
DB	DB	SMELTZER, et al., "Synthesis and characterization of fluorescent cobalamin (cobalafuor) derivatives for imaging, <i>Organic Letters</i> , 3(6), 799-801 (2001).	
DC	DC	VARES, Y.V., et al., "Kinetic of 57 Co-cyanocobalamin distribution in organs and tissues of mice with transplanted tumours", <i>Eksp. Onkol</i> , 8, Abstract, 33-36 (1986).	
DD	DD	WILBUR, et al., "Biotin Reagents for Antibody Pretargeting. 4. Selection of Biotin Conjugates for in Vivo Application Based on Their Dissociation Rate from Avidin and Streptavidin." <i>Bioconjugate Chem.</i> , 11(4), 569-583 (June 29, 2000).	
DE	DE	WILBUR, et al., "Evaluation of Biotin-Dye Conjugates for Use in an HPLC Assay to Assess Relative Binding of Biotin Derivatives with Avidin and Streptavidin." <i>Bioconjugate Chem.</i> , 11(4), 584-598 (June 29, 2000).	
DF	DF	WOOLLEY, K.E., et al., "Uptake of [Co-57]-vitamin B-12 by murine tumours of many histological types", <i>Clin. Res.</i> , 41, Abstracts of National Meeting, Assoc. Amer. Physicians, p. 73A (April 1993).	
DG	DG	WU, C., et al., "Investigation of N-linked macrocycles for 111In and 90Y labeling of proteins, <i>Nucl. Med. Biol.</i> , 19, 239-244 (1992).	

3316669\_2

Examiner  
Signature

D. Jones

Date  
Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

### Complete if Known

Application Number	10/620,273
Filing Date	July 15, 2003
First Named Inventor	C Collins, et al.
Group Art Unit	Unassigned 1614
Examiner Name	Unassigned D. Jones
Attorney Docket Number	07959.105018 COP 1000 DIV 5

3349747\_1

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JD	AA	5,608,060	B	AXWORTHY, et al.	03-04-1997	
JD	AB	5,877,165	B	MIURA, et al.	03-02-1999	
JD	AC	6,183,723	B	SEETHARAM, et al.	02-06-2001	
JD	AD	2003-0144198	A	COLLINS, et al.	07-31-2003	

Class/Sub



### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office	Number	Kind Code (if known)				
JD	AE	WO	00/45857	A2, A3	LAWACZECK, et al.	08-10-2000		
JD	AF	WO	00/62808	A2, A3	COLLINS, et al.	10-26-2000		
JD	AG	WO	01/92283	A2	COLLINS, et al.	12-6-2001		
JD	AH	WO	03/00010	A2, A3	COLLINS, et al.	01-21-2003		
JD	AI	WO	03/25139	A2, A3	COLLINS, et al.	03-27-2003		

Class/Sub



### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
JD	AJ	ALLEN, R.H., et al., "Isolation of Gastric Vitamin B12-binding Proteins Using Affinity Chromatography," <i>Journal of Biological Chemistry</i> , 248(10), 3660-3669 (1973).	
JD	AK	ALLEN, R.H., et al., "Isolation of Vitamin B12-binding Proteins Using Affinity Chromatography," <i>Journal of Biological Chemistry</i> , 247(23), 7695-7701 (1972).	
JD	AL	ALLEN, R.H., "Human Vitamin B12 Transport Proteins," <i>Progress in Hematology</i> , Vol. 9, , pp. 57-84 (1975)	
JD	AM	COLLINS, D., et al., "Tumor Imaging via Indium 111-Labeled DTPA-Adenosylcobalamin", <i>Mayo Clinic Proc.</i> , 74, 687-691 (1999).	
JD	AN	COLLINS, D.A., et al., "Transcobalamin II imaging via radiolabeled diethylene-triaminepentaacetate cobalamin analogs", <i>J. Nucl. Med.</i> , 38(5), 717-723 (1997).	
JD	AO	FEDOSOV, S.N., et al., "Binding of Cobalamin and Cobinamide to Transcobalamin from Bovine Milk," <i>Biochemistry</i> , 34, 16082-16087 (1995).	
JD	AP	FEDOSOV, S.N., et al., "Transcobalamin from cow milk: isolation and physico-chemical properties," <i>Biochimica et Biophysica Acta</i> , 1292, 113-119, (1996).	

Examiner Signature

*D. Jones*


Date Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

### Complete if Known

Application Number	10/620,273
Filing Date	July 15, 2003
First Named Inventor	Collins, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned Jones
Attorney Docket Number	07959.105018 COP 1000 DIV 5

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
[Signature]	BA	FINKLER, A.E., et al., "Nature of the Relationship between Vitamin B12 Binding and Cell Uptake," <i>Archives of Biochemistry and Biophysics</i> , 120, 79-85 (1967).	
	BB	HALL, C.A., et al., "Cyclic Activity of the Receptors of Cobalamin Bound to Transcobalamin II," <i>Journal of Cellular Physiology</i> , 133(1), 187-191 (1987).	
	BC	HOGENKAMP, H., et al., "Synthesis and Characterization of nido-Carborane-Cobalamin Conjugates", <i>Nucl. Med. &amp; Biol.</i> , 27, 89-92 (2000).	
	BD	HOGENKAMP, H.P.C., et al., "Diagnostic and Therapeutic Analogues of Cobalamin", <i>Chemistry and Biochemistry of B<sub>12</sub></i> , R. Banerjee, ed.; Wiley & Sons (1999), Part II, Section 15, pp. 385-410.	
	BE	MCLEAN, G.R., et al., "Antibodies to Transcobalamin II Block In Vitro Proliferation of Leukemic Cells," <i>Blood</i> , 89(1), 235-242 (1997).	
	BF	NEXØ, E., "Cobalamin Binding Proteins," in <i>Vitamin B12 and B12-proteins</i> , eds. Krantler, B.; Arigoni, D. and Golding, B.T.; Wiley & Sons, Ltd. pp. 461-475.	
	BG	RAPPAZZO, M.E., et al., "Transport Function of Transcobalamin II," <i>Journal of Clinical Investigation</i> , 51, 1915-1918 (1972).	
	BH	SODA, R., et al., "Receptor Distribution and the Endothelial Uptake of Transcobalamin II in Liver Cell Suspensions," <i>Blood</i> , 65(4), 795-802 (1985).	
	BI	UCHINO, H., et al., "Tissue Distribution of Coenzyme B <sub>12</sub> in Rats Following Intravenous Administration," <i>Annals of the New York Academy of Sciences</i> , 112(Art. 2), 844-854 (1964).	

3349747\_1

Examiner  
Signature

[Signature]

Date  
Considered

2/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.